Mantle Cell Lymphoma International Prognostic Index (MIPI)

• The MIPI categorizes patients into 3 risk groups: low, intermediate, or high.
• Low-risk patients may be considered for close observation if there are no other indications for treatment.
• However, both intermediate and high risk patients are treated with immunochemotherapy either alone or followed by autologous stem cell transplantation depending on many other patient factors such as age, comorbidities, side effect profiles, and patient preferences.

There is diversity in clinical practice for the treatment of mantle cell lymphoma, with very few head-to-head studies of the various approaches. While we know a small number of patients with low-burden, low-risk disease may have an indolent course, it is difficult to identify those patients at diagnosis. Most patients will need treatment at diagnosis even though current treatment paradigms are not considered curative. The standard treatments are induction chemoimmunotherapy followed by autologous stem cell transplantation with or without maintenance.